Quick Answer
TANDEM DIABETES CARE INC reported Cash and Equivalents of $90.63 million for fiscal year 2025.
TANDEM DIABETES CARE INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $90.63M | +30.9% |
| 2024 | $69.23M | +17.6% |
| 2023 | $58.87M | -65.9% |
| 2022 | $172.52M | +142.4% |
| 2021 | $71.18M | -24.8% |
| 2020 | $94.61M | +84.9% |
| 2019 | $51.17M | +22.4% |
| 2018 | $41.83M | +205.3% |
| 2017 | $13.70M | -69.3% |
| 2016 | $44.68M | +3.7% |
| 2015 | $43.09M | +38.2% |
| 2014 | $31.18M | -74.9% |
| 2013 | $124.39M | +624.7% |
| 2012 | $17.16M | +98.3% |
| 2011 | $8.66M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $91.95M | +87.5% | +43.4% |
| June 30, 2025 | $64.11M | +34.4% | +19.7% |
| March 31, 2025 | $53.57M | -9.2% | -22.6% |
| December 31, 2024 | $69.23M | +17.6% | +41.2% |
| September 30, 2024 | $49.04M | -38.4% | +2.8% |
| June 30, 2024 | $47.70M | -63.5% | -19.1% |
| March 31, 2024 | $58.98M | -53.8% | +0.2% |
| December 31, 2023 | $58.87M | -65.9% | -26.1% |
- TANDEM DIABETES CARE INC showed an increase of +30.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, TANDEM DIABETES CARE INC’s cash and equivalents has grown by 946.9% (from $8.66 million to $90.63 million).
- The most recent figure is from TANDEM DIABETES CARE INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: